STAT3 and cancer: Previous studies have confirmed that MET is a significant driver of mutation in NSCLC, activating signaling pathways downstream of PI3K/AKT, Ras-MAPK, and STAT3 (signal transducer and activator of transcription 3), which promote cancer proliferation, migration, and invasion [4].